A detailed history of Vanguard Group Inc transactions in Clene Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,622,157 shares of CLNN stock, worth $14.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,622,157
Previous 2,619,703 0.09%
Holding current value
$14.9 Million
Previous $1.13 Million 16.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.31 - $0.44 $760 - $1,079
2,454 Added 0.09%
2,622,157 $943,000
Q1 2024

May 10, 2024

BUY
$0.28 - $0.53 $368 - $696
1,315 Added 0.05%
2,619,703 $1.13 Million
Q4 2023

Feb 14, 2024

BUY
$0.26 - $0.55 $44,842 - $94,859
172,471 Added 7.05%
2,618,388 $785,000
Q3 2023

Nov 14, 2023

BUY
$0.46 - $0.87 $112,948 - $213,619
245,540 Added 11.16%
2,445,917 $1.22 Million
Q2 2023

Aug 14, 2023

BUY
$0.78 - $1.22 $842,088 - $1.32 Million
1,079,601 Added 96.33%
2,200,377 $1.94 Million
Q1 2023

May 15, 2023

BUY
$0.95 - $1.62 $179,282 - $305,723
188,718 Added 20.25%
1,120,776 $1.27 Million
Q4 2022

Feb 10, 2023

BUY
$0.92 - $40.2 $409 - $17,889
445 Added 0.05%
932,058 $932,000
Q3 2022

Nov 14, 2022

BUY
$0.33 - $73.0 $39,297 - $8.69 Million
119,084 Added 14.66%
931,613 $2.61 Million
Q2 2022

Aug 12, 2022

BUY
$2.1 - $4.12 $47,388 - $92,971
22,566 Added 2.86%
812,529 $2.05 Million
Q1 2022

May 13, 2022

SELL
$2.42 - $4.42 $529,670 - $967,414
-218,872 Reduced 21.7%
789,963 $3.11 Million
Q4 2021

Feb 14, 2022

SELL
$3.95 - $7.53 $454,992 - $867,365
-115,188 Reduced 10.25%
1,008,835 $4.14 Million
Q3 2021

Nov 12, 2021

SELL
$6.83 - $13.58 $55,042 - $109,441
-8,059 Reduced 0.71%
1,124,023 $7.68 Million
Q2 2021

Aug 13, 2021

BUY
$6.98 - $13.33 $7.9 Million - $15.1 Million
1,132,082 New
1,132,082 $12.7 Million

Others Institutions Holding CLNN

About Clene Inc.


  • Ticker CLNN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 63,502,000
  • Market Cap $360M
  • Description
  • Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...
More about CLNN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.